Antibiotic Resistance Global Market Report 2024

Description

Antimicrobial resistance refers to the phenomenon where microorganisms, including bacteria and fungi, develop the ability to withstand the effects of medications designed to eliminate them. This resistance poses a significant challenge in the treatment of infections and, in severe cases, can lead to fatalities.

The primary classes of drugs associated with antibiotic resistance include beta-lactam antibiotics, cephalosporins, quinolone antibiotics, macrolide antibiotics, tetracyclines, oxazolidinones, and others. Beta-lactam antibiotics, characterized by a beta-lactam ring in their chemical structure, work by preventing the construction of bacterial cell walls. They achieve this by covalently binding to crucial penicillin-binding proteins (PBPs), inhibiting the growth of organisms. Pathogens affected by these drugs include Staphylococcus aureus, Staphylococcus pneumonia, Neisseria gonorrhoeae, Enterococcus faecium, Escherichia coli, Klebsiella pneumonia, Shigella, Clostridium difficile, among others. These drugs are employed in the treatment of various diseases such as urinary tract infections, intra-abdominal infections, bloodstream infections, and Clostridium difficile infections. The mechanisms of action encompass protein synthesis inhibitors, cell wall synthesis inhibitors, RNA synthesis inhibitors, DNA synthesis inhibitors, and others. These drugs are utilized by diverse end-users, including hospitals, homecare, specialty clinics, and more.

The antibiotic resistance market research report is one of a series of new reports from The Business Research Company that provides antibiotic resistance market statistics, including the antibiotic resistance industry global market size, regional shares, competitors with an antibiotic resistance market share, detailed antibiotic resistance market segments, market trends, and opportunities, and any further data you may need to thrive in the antibiotic resistance industry. This antibiotic resistance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antibiotic resistance market size has grown strongly in recent years. It will grow from $11.43 billion in 2023 to $12.13 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to several factors, including the absence of new antibiotics, the misuse and overuse of antimicrobials in humans, animals, and plants, highly contaminated waste effluents, low vaccination rates, and a lack of diagnostic tools.

The antibiotic resistance market size is expected to see strong growth in the next few years. It will grow to $15.47 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to factors such as incomplete treatment courses, globalization and travel, poor infection prevention and control, self-medication, cross-species transmission, and high population density. Major trends in the forecast period include technological innovations in drug delivery, global collaboration for surveillance, expanding the role of artificial intelligence, and a surge in novel therapies.

The surge in drug-resistant infections is anticipated to be a significant driver for the expansion of the antibiotic-resistance market. These infections, caused by bacteria resistant to drugs, pose challenges in curing or treating the diseases they cause. Antimicrobial resistance drugs play a crucial role in managing various drug-resistant infections, improving treatment outcomes for both target and non-target pathogens. An example from November 2022, provided by the European Centre for Disease Prevention and Control, highlighted that approximately 35,000 individuals in the EU/EEA succumb annually to antimicrobial-resistant diseases. Furthermore, instances of Klebsiella pneumoniae infections increased by 20% in 2021, and reported cases of Candida auris nearly doubled between 2020 and 2021, emphasizing the driving force behind the antibiotic resistance market due to the prevalence of drug-resistant infections.

The escalation in healthcare expenditure is poised to fuel the growth trajectory of the antibiotic resistance market. Healthcare expenditure denotes the cumulative financial resources invested in healthcare-related goods and services within a specified timeframe. Increased healthcare spending plays a pivotal role in propelling the antibiotic resistance market by fostering heightened research, development, and adoption of innovative treatments to counter the challenges posed by antibiotic-resistant infections. Notably, as per the 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services in March 2022, projections indicate an estimated annual growth rate of 5.1% in national health spending between 2021 and 2030, reaching nearly $6.8 trillion. Moreover, the anticipated annual growth rates of 7.2% for Medicare spending and 5.6% for Medicaid spending from 2021 to 2030 underscore the substantial contribution of growing healthcare expenditure to the expansion of the antibiotic resistance market.

The antibiotic resistance market is witnessing a prominent trend centered on product innovations. Key players within this market are dedicated to pioneering innovative products to solidify their market presence. For instance, in January 2023, Alkem Laboratories Limited, an India-based pharmaceutical firm, introduced Zidavi. This novel antibiotic, a combination of ceftazidime and avibactam, addresses multi-drug resistant (MDR) infections, ensuring accessibility, affordability, and availability for critically ill patients. Zidavi, available in sterile powdered concentrate for reconstitution, offers a distinctive solution for treating infections caused by MDR gram-negative pathogens. Its formulation in single-dose vials provides an effective alternative for treating hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) linked to meropenem and colistin resistance.

Major enterprises in the antibiotic resistance market are strategically fostering partnerships to innovate and create the next generation of antimicrobial agents alongside practical diagnostics in the fight against Antimicrobial Resistance (AMR). These strategic collaborations involve leveraging complementary strengths and resources to achieve mutual success. For example, in July 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, and Evotec SE, a German biotechnology firm, joined forces with bioMerieux, a France-based diagnostic solutions provider. This partnership resulted in the formation of Aurobac Therapeutics SAS, aiming to pioneer a novel precision medicine strategy spanning diagnosis to treatment by harnessing the collective expertise of the founding companies. Their collaborative efforts aim to develop innovative antimicrobials coupled with effective diagnostics to counter the challenge posed by Antimicrobial Resistance (AMR).

In July 2022, Innoviva Inc., a pharmaceutical company based in the United States, successfully acquired Entasis Therapeutics Holdings Inc for an undisclosed sum. This strategic acquisition is designed to enhance Innoviva Inc's product portfolio focused on addressing multidrug-resistant gram-negative bacteria, providing a competitive edge in the market. Entasis Therapeutics Holdings Inc., a US-based company, specializes in the development of innovative antibacterial solutions for the treatment of severe bacterial infections resistant to conventional drugs.

Major companies operating in the antibiotic resistance market report are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Merck and Co. Inc., Bristol-Myers Squibb, Sanofi S.A., Thermo Fisher Scientific Inc., AstraZeneca, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Bio-Rad Laboratories Inc., Eppendorf Corporation, Takara Bio Inc., Wockhardt Ltd., Paratek Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Theravance Biopharma Inc., Nabriva Therapeutics PLC, Seres Therapeutics Inc., Armata Pharmaceuticals Inc.

North America was the largest region in the antibiotic resistance market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotic resistance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antibiotic resistance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antibiotic resistance market consists of sales of antibiotic drug classes such as carbapenems, glycopeptide antibiotics, penicillin, fluoroquinolones, trimethoprim-sulfamethoxazole, lincosamides, aminoglycosides, polymyxins, and nitroimidazoles. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibiotic Resistance Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibiotic resistance market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antibiotic resistance ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibiotic resistance market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Drug Class: Beta Lactum Antibiotic; Cephalosporins; Quinolones Antibiotics; Macrolide Antibiotics; Tetracyclines; Oxazolidinones; Other Drug Classes
2) By Pathogen: Staphylococcus aureus; Staphylococcus pneumonia; Neisseria gonorrhoeae; Enterococcus Faecium; Escherichia coli; Klebsiella pneumonia; Shigella; Clostridium difficile; Other pathogens
3) By Disease Type: Urinary tract infection; Intra-abdominal infection; Blood stream infections; Clostridium difficile infections; Other Disease Types
4) By Mechanism of Action: Protein Synthesis Inhibitors; Cell Wall Synthesis Inhibitors; RNA Synthesis Inhibitors; DNA Synthesis Inhibitors; Other Mechanism Of Actions
5) By End Users: Hospitals; Homecare; Specialty clinics; Other End-users
Companies Mentioned: Pfizer Inc.; Johnson and Johnson; F. Hoffmann-La Roche Ltd; AbbVie Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13542

1. Executive Summary

2. Antibiotic Resistance Market Characteristics

3. Antibiotic Resistance Market Trends And Strategies

4. Antibiotic Resistance Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Antibiotic Resistance Market Size and Growth

5.1. Global Antibiotic Resistance Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Antibiotic Resistance Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Antibiotic Resistance Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antibiotic Resistance Market Segmentation

6.1. Global Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Beta Lactum Antibiotic
Cephalosporins
Quinolones Antibiotics
Macrolide Antibiotics
Tetracyclines
Oxazolidinones
Other Drug Classes
6.2. Global Antibiotic Resistance Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Staphylococcus aureus
Staphylococcus pneumonia
Neisseria gonorrhoeae
Enterococcus Faecium
Escherichia coli
Klebsiella pneumonia
Shigella
Clostridium difficile
Other pathogens
6.3. Global Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Urinary tract infection
Intra-abdominal infection
Blood stream infections,
Clostridium difficile infections
Other Disease Type
6.4. Global Antibiotic Resistance Market, Segmentation By Mechanism of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Protein Synthesis Inhibitors
Cell Wall Synthesis Inhibitors
RNA Synthesis Inhibitors
DNA Synthesis Inhibitors
Other Mechanism of actions
6.5. Global Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End-users

7. Antibiotic Resistance Market Regional And Country Analysis

7.1. Global Antibiotic Resistance Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Antibiotic Resistance Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antibiotic Resistance Market

8.1. Asia-Pacific Antibiotic Resistance Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antibiotic Resistance Market

9.1. China Antibiotic Resistance Market Overview
9.2. China Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antibiotic Resistance Market

10.1. India Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antibiotic Resistance Market

11.1. Japan Antibiotic Resistance Market Overview
11.2. Japan Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antibiotic Resistance Market

12.1. Australia Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antibiotic Resistance Market

13.1. Indonesia Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antibiotic Resistance Market

14.1. South Korea Antibiotic Resistance Market Overview
14.2. South Korea Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antibiotic Resistance Market

15.1. Western Europe Antibiotic Resistance Market Overview
15.2. Western Europe Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antibiotic Resistance Market

16.1. UK Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antibiotic Resistance Market

17.1. Germany Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antibiotic Resistance Market

18.1. France Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antibiotic Resistance Market

19.1. Italy Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antibiotic Resistance Market

20.1. Spain Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antibiotic Resistance Market

21.1. Eastern Europe Antibiotic Resistance Market Overview
21.2. Eastern Europe Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antibiotic Resistance Market

22.1. Russia Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antibiotic Resistance Market

23.1. North America Antibiotic Resistance Market Overview
23.2. North America Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antibiotic Resistance Market

24.1. USA Antibiotic Resistance Market Overview
24.2. USA Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antibiotic Resistance Market

25.1. Canada Antibiotic Resistance Market Overview
25.2. Canada Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antibiotic Resistance Market

26.1. South America Antibiotic Resistance Market Overview
26.2. South America Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antibiotic Resistance Market

27.1. Brazil Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antibiotic Resistance Market

28.1. Middle East Antibiotic Resistance Market Overview
28.2. Middle East Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antibiotic Resistance Market

29.1. Africa Antibiotic Resistance Market Overview
29.2. Africa Antibiotic Resistance Market, Segmentation By Drug Class , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Antibiotic Resistance Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Antibiotic Resistance Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antibiotic Resistance Market Competitive Landscape And Company Profiles

30.1. Antibiotic Resistance Market Competitive Landscape
30.2. Antibiotic Resistance Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson and Johnson
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. F. Hoffmann-La Roche Ltd
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AbbVie Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Antibiotic Resistance Market Other Major And Innovative Companies

31.1. Merck and Co. Inc.
31.2. Bristol-Myers Squibb
31.3. Sanofi S.A.
31.4. Thermo Fisher Scientific Inc
31.5. AstraZeneca
31.6. GlaxoSmithKline Plc
31.7. Eli Lilly and Company
31.8. Boehringer Ingelheim International GmbH
31.9. Astellas Pharma
31.10. Daiichi Sankyo
31.11. Chugai Pharmaceutical Co. Ltd.
31.12. Teva Pharmaceutical Industries Ltd.
31.13. Bio-Rad Laboratories Inc
31.14. Eppendorf Corporation
31.15. Takara Bio Inc

32. Global Antibiotic Resistance Market Competitive Benchmarking

33. Global Antibiotic Resistance Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Antibiotic Resistance Market

35. Antibiotic Resistance Market Future Outlook and Potential Analysis

35.1 Antibiotic Resistance Market In 2028 - Countries Offering Most New Opportunities
35.2 Antibiotic Resistance Market In 2028 - Segments Offering Most New Opportunities
35.3 Antibiotic Resistance Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer